MX2022001741A - Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina. - Google Patents
Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina.Info
- Publication number
- MX2022001741A MX2022001741A MX2022001741A MX2022001741A MX2022001741A MX 2022001741 A MX2022001741 A MX 2022001741A MX 2022001741 A MX2022001741 A MX 2022001741A MX 2022001741 A MX2022001741 A MX 2022001741A MX 2022001741 A MX2022001741 A MX 2022001741A
- Authority
- MX
- Mexico
- Prior art keywords
- salt
- compound
- crystalline forms
- forms
- kinase inhibitor
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- 229940123593 Activin receptor-like kinase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
- 206010068715 Fibrodysplasia ossificans progressiva Diseases 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000000053 physical method Methods 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical group OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962885977P | 2019-08-13 | 2019-08-13 | |
| PCT/US2020/045847 WO2021030386A1 (en) | 2019-08-13 | 2020-08-12 | Salt and crystal forms of an activin receptor-like kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001741A true MX2022001741A (es) | 2022-03-11 |
Family
ID=72193669
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001741A MX2022001741A (es) | 2019-08-13 | 2020-08-12 | Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina. |
| MX2024014312A MX2024014312A (es) | 2019-08-13 | 2022-02-09 | Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024014312A MX2024014312A (es) | 2019-08-13 | 2022-02-09 | Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220281879A1 (https=) |
| EP (1) | EP4013757A1 (https=) |
| JP (2) | JP7775186B2 (https=) |
| KR (1) | KR20220052955A (https=) |
| CN (2) | CN119638704A (https=) |
| BR (1) | BR112022002597A2 (https=) |
| CA (1) | CA3146701A1 (https=) |
| CO (1) | CO2022001450A2 (https=) |
| IL (1) | IL290482A (https=) |
| JO (1) | JOP20220014A1 (https=) |
| MX (2) | MX2022001741A (https=) |
| TW (1) | TWI870440B (https=) |
| UA (1) | UA130650C2 (https=) |
| WO (1) | WO2021030386A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109311889B (zh) * | 2016-04-15 | 2021-11-16 | 缆图药品公司 | 激活素受体样激酶抑制剂 |
| EP3870181B1 (en) | 2018-10-26 | 2024-08-14 | Keros Therapeutics, Inc. | Crystal forms of an alk2 inhibitor |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109311889B (zh) * | 2016-04-15 | 2021-11-16 | 缆图药品公司 | 激活素受体样激酶抑制剂 |
| AR112027A1 (es) * | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
-
2020
- 2020-08-12 TW TW109127433A patent/TWI870440B/zh active
- 2020-08-12 CN CN202411831775.3A patent/CN119638704A/zh active Pending
- 2020-08-12 US US17/633,440 patent/US20220281879A1/en active Pending
- 2020-08-12 UA UAA202200733A patent/UA130650C2/uk unknown
- 2020-08-12 EP EP20761085.8A patent/EP4013757A1/en active Pending
- 2020-08-12 CA CA3146701A patent/CA3146701A1/en active Pending
- 2020-08-12 JO JOP/2022/0014A patent/JOP20220014A1/ar unknown
- 2020-08-12 KR KR1020227008160A patent/KR20220052955A/ko active Pending
- 2020-08-12 BR BR112022002597A patent/BR112022002597A2/pt unknown
- 2020-08-12 MX MX2022001741A patent/MX2022001741A/es unknown
- 2020-08-12 JP JP2022508779A patent/JP7775186B2/ja active Active
- 2020-08-12 CN CN202080057092.0A patent/CN114222745B/zh active Active
- 2020-08-12 WO PCT/US2020/045847 patent/WO2021030386A1/en not_active Ceased
-
2022
- 2022-02-09 MX MX2024014312A patent/MX2024014312A/es unknown
- 2022-02-09 IL IL290482A patent/IL290482A/en unknown
- 2022-02-14 CO CONC2022/0001450A patent/CO2022001450A2/es unknown
-
2025
- 2025-07-04 JP JP2025113638A patent/JP2025148406A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022544272A (ja) | 2022-10-17 |
| CN114222745A (zh) | 2022-03-22 |
| BR112022002597A2 (pt) | 2022-07-05 |
| CN114222745B (zh) | 2025-03-25 |
| CA3146701A1 (en) | 2021-02-18 |
| WO2021030386A1 (en) | 2021-02-18 |
| CO2022001450A2 (es) | 2022-05-31 |
| CN119638704A (zh) | 2025-03-18 |
| AU2020328534A1 (en) | 2022-03-17 |
| JP2025148406A (ja) | 2025-10-07 |
| EP4013757A1 (en) | 2022-06-22 |
| IL290482A (en) | 2022-04-01 |
| KR20220052955A (ko) | 2022-04-28 |
| TWI870440B (zh) | 2025-01-21 |
| JOP20220014A1 (ar) | 2023-01-30 |
| MX2024014312A (es) | 2024-12-06 |
| TW202120509A (zh) | 2021-06-01 |
| UA130650C2 (uk) | 2026-04-08 |
| JP7775186B2 (ja) | 2025-11-25 |
| US20220281879A1 (en) | 2022-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022001450A2 (es) | Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina | |
| PH12020550644A1 (en) | Crystalline forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | |
| PH12021553233A1 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| CY1122468T1 (el) | Κρυσταλλικη μορφη διθειικου αναστολεα κινασης jak και μια μεθοδος παρασκευης αυτου | |
| MX376500B (es) | Forma cristalina del inhibidor de la btk quinasa y método de preparación de la misma. | |
| PH12020550575A1 (en) | Salts of pi3k inhibitor and processes for their preparation | |
| MX384087B (es) | Piperidinas como inhibidores de menina. | |
| EP4248988A3 (en) | Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell | |
| SA520411638B1 (ar) | Tam أملاح لمشتقات بيرولو ترايازين مفيدة كمثبطات لـ | |
| MX2019012945A (es) | Formas cristalinas de un compuesto inhibidor de jak. | |
| MY188447A (en) | Indazole compounds as fger kinase inhibitor, preparation and use thereof | |
| MX2020004148A (es) | Sales cristalinas de un inhibidor de cinasa de fibrosarcoma acelerado rapidamente (b-raf). | |
| WO2018044767A3 (en) | Aminopyrimidines as alk inhibitors | |
| MA40059A (fr) | Inhibiteurs de la phosphatidylinositol 3-kinase | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| MX2019011116A (es) | Inhibidores de la tirosina quinasa de bruton. | |
| WO2015019238A8 (en) | Process for the preparation of n-protected (5s)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-one | |
| CO2020001861A2 (es) | Inhibidores de ror gamma | |
| MX2022001608A (es) | Sintesis de un inhibidor de calicreina plasmatica a escala de proceso. | |
| MX2020005332A (es) | Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion. | |
| PY1976957A (es) | Formas cristalinas de un compuesto de quinazolina y sus sales de clorhidrato.- | |
| MX2023004115A (es) | Compuestos del inhibidor de la autotaxina. | |
| AR110998A1 (es) | Inhibidores de la tirosina cinasa de bruton | |
| MX2020009412A (es) | Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido. | |
| SA522431923B1 (ar) | عملية لتحضير دواء |